TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT03603223: Pembrolizumab in Treating Participants With Leukoplakia

Sponsor: Jonsson Comprehensive Cancer Center · Phase: PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 26 pts

Competing Trials Overlap

4 Active Trials

Excess Burn Exposure

$730,400

Rescue Site Savings

+$498,000

Unlock Full NCT03603223 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT03603223 Rescue Dossier →